We are live on ! Find out more
TNYA icon

Tenaya Therapeutics

68 hedge funds and large institutions have $94.7M invested in Tenaya Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

7% less funds holding

Funds holding: 7368 (-5)

7% less capital invested

Capital invested by funds: $102M → $94.7M (-$7.41M)

11.55% less ownership

Funds ownership: 85.19%73.64% (-12%)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

84% less call options, than puts

Call options by funds: $12K | Put options by funds: $76K

Holders
68
Holders Change
-5
Holders Change %
-6.85%
% of All Funds
1.09%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
15
Increased
25
Reduced
14
Closed
20
Calls
$12K
Puts
$76K
Net Calls
-$64K
Net Calls Change
+$81K
Name Holding Trade Value Shares
Change
Change in
Stake
PM
26
Prosight Management
Texas
$215K +$261K +107,063 New
BCM
27
Bridgeway Capital Management
Texas
$206K +$250K +102,300 New
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$196K -$388K -159,004 -62%
Two Sigma Investments
29
Two Sigma Investments
New York
$161K +$115K +46,919 +141%
Bank of America
30
Bank of America
North Carolina
$157K +$128K +52,459 +205%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$153K
JRP
32
Jasper Ridge Partners
California
$127K +$33.1K +13,573 +27%
Charles Schwab
33
Charles Schwab
California
$123K -$12.1K -4,937 -7%
Squarepoint
34
Squarepoint
New York
$123K +$149K +61,167 New
N
35
Nuveen
North Carolina
$110K -$54K -22,128 -29%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$85K +$344 +141 +0.3%
Goldman Sachs
37
Goldman Sachs
New York
$82.3K +$3.47K +1,423 +4%
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$78.9K -$15.8K -6,488 -14%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$76K +$23.3K +9,552 +34%
Morgan Stanley
40
Morgan Stanley
New York
$56K +$33.2K +13,601 +95%
OQS
41
Occudo Quantitative Strategies
Florida
$53.6K +$1.63K +666 +3%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$41.4K +$50.3K +20,600 New
CSS
43
Cubist Systematic Strategies
Connecticut
$40.7K -$8.74K -3,581 -15%
JP Morgan Chase
44
JP Morgan Chase
New York
$35K +$51 +21 +0.1%
Barclays
45
Barclays
United Kingdom
$30.7K +$15.4K +6,319 +71%
E
46
Ergoteles
New York
$28.7K +$34.8K +14,261 New
AIG
47
American International Group
New York
$26.6K -$117 -48 -0.4%
Jane Street
48
Jane Street
New York
$25.1K +$30.5K +12,501 New
Deutsche Bank
49
Deutsche Bank
Germany
$25K +$459 +188 +2%
UBS Group
50
UBS Group
Switzerland
$24.2K +$29.4K +12,060 New

TNYA Hedge Fund Activity: Q4 2022 in Review

68 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q4 2022, worth a combined $94.7M — down 7.3% from $102M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of TNYA and 15 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 25 added.

The largest buyer was RA Capital Management, adding an estimated $10.9M. The largest seller was Fidelity Investments, cutting an estimated $720K.

  • 68 institutional investors held Tenaya Therapeutics (TNYA) as of Q4 2022, down from 73 in Q3 2022.
  • Funds reported $94.7M of Tenaya Therapeutics stock for Q4 2022, down 7.3% quarter-over-quarter.
  • 15 funds opened new Tenaya Therapeutics positions in Q4 2022 and 20 closed out, a net change of -5 holders.
  • The largest Tenaya Therapeutics buyer in Q4 2022 was RA Capital Management, an estimated $10.9M added.
  • The largest Tenaya Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $720K sold.

Based on aggregated 13F filings for Q4 2022.